Like KRAS mutation, MYC deregulation in cancer cells fosters an immunosuppressive TIME by both altering the protein expression profile within the deregulated tumor cells and attracting immunosuppressive cells to the tumor site.16,116,306 On one hand, deregulated MYC directly affects the process of immunoediting, causing increased expression of nuclear Aurora kinase A (AURKA), which, in turn, induces the expression of PD-L1,307 and upregulation of CD47308 on tumor cells, protecting them from the attack of T cells and macrophages. Here, KRAS is linked to cancer.